Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Mod GRF 1-29

Sermorelin, Growth Hormone Releasing Hormone (1-29), hGRF(1-29)NH2

Quick Stats
Studies 227
Trials 47
Score 4
1991 pubmed

In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma.

Su. C M CM; Jensen. L R LR; Heimer. E P EP; Felix. A M AM; Pan. Y C YC; Mowles. T F TF

Key Findings

  • Unmodified GRF(1‑29)-NH2 is rapidly degraded in plasma (t½ ≈ 13 min), mainly to GRF(3‑29)-NH2.
  • Cyclizing side‑chains between Asp8 and Lys12 (and optionally also Lys21‑Asp25) boosts plasma stability to >2 hours.
  • Introducing D‑Ala at position 2 and/or using a D‑amino acid at the penultimate spot further prolongs the peptide’s half‑life.

Practical Outcomes

  • For biohackers, using GRF analogs that are cyclized or contain D‑amino acids can give a much longer window of action, meaning fewer injections and more stable growth‑hormone release. When choosing a GHRH product, look for versions marketed as “cyclic” or “D‑amino acid‑modified” (e.g., CJC‑1295 or custom‑synthesized analogs) to take advantage of this increased stability.

Summary

The study shows that the plain growth‑hormone‑releasing factor peptide (GRF‑1‑29) disappears from blood very fast—its half‑life is only about 13 minutes. By swapping a few building blocks or by linking parts of the molecule together (cyclization) and using D‑amino acids, the peptide can stay intact for over two hours. These changes dramatically slow down the breakdown that normally limits how long the peptide works.

Abstract

The stability of growth-hormone releasing factor (growth regulating factor; GRF) analogs in porcine plasma was examined. GRF analogs were incubated in porcine plasma at 37 degrees C, extracted and subsequently analyzed using high performance liquid chromatography (HPLC). GRF(1-29)-NH2 was rapidly broken down in the plasma with a degradation rate of t1/2 = 13 min. The primary degradation product was identified as GRF(3-29)-NH2. Substitution of Gly15 by Ala15 slightly prolonged the plasma half-life (t1/2 = 17 min) and the major degradative fragment was found to be [Ala15]GRF(3-29)-NH2. The cleavage between the 2 and 3 position of the peptide was not inhibited by trasylol at a concentration of 1,000 KIU/ml but was dramatically reduced by the combined use of diprotin A and trasylol. Absence of the free amino group at the N-terminus and/or substitution of a D-amino acid residue at the penultimate position completely prevented cleavage between the 2 and 3 position in the structural linear GRF analogs. Side-chain to side-chain cyclization between Asp8 and Lys12 amino acid residues significantly improved the stability of GRF in plasma with t1/2 greater than 2 hr. An additional stability was provided by substitution of D-Ala2 for Ala2 in the structural cyclic analog. Cyclization between Lys21 and Asp25 also improved the stability of the GRF peptide in the plasma. Stability was further enhanced by the presence of D-Ala2 or by forming a dicyclic analog through an additional linkage between Asp8 and Lys12.

Study Information

Provider

pubmed

Year

1991

Date

1991-01-01T00:00:00.000Z

DOI

10.1055/s-2007-1003601

References

24